Previous 10 | Next 10 |
Credit Suisse has initiated Exelixis ( NASDAQ: EXEL ) with an outperform rating saying that its core medicine, Cabometyx (cabozantinib) is ma market leader and has growth potential with its pipeline. The firm has a $29 price target (67% upside based on Wednesday's close). Analyst ...
– Conference Call and Webcast to Follow at 5: 00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the markets close. At 5:00 p...
Update 8:15pm: Adds Exelixis comment. Exelixis ( NASDAQ: EXEL ) had a mixed ruling in its Cabometyx patent trial versus MSN Laboratories. Exelixis rose 2.8% in after hours trading. The judge in the patent case ruled that the 776 patent, which goes to October 2030, wasn'...
Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. ( MSN ), Action No. 19-2017 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s...
Exelixis ( NASDAQ: EXEL ) had a mixed ruling in its Cabometyx patent trial versus MSN Laboratories. Exelixis rose 1% in after hours trading. The judge in the patent case ruled that the 776 patent, which goes to October 2030, wasn't infringed, a defeat for Exelixis. ...
The following slide deck was published by Exelixis, Inc. in conjunction with this event. For further details see: Exelixis (EXEL) Presents at 41st Annual Healthcare Conference -Slideshow
Summary Exelixis' CABOMETYX is hitting on all cylinders. Exelixis has an interesting and highly cabozantinib-centric pipeline. Pharma BD is a tricky process that will play a big role in Exelixis' future. This is my first look at Exelixis ( EXEL ). It is a young commerc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they’re seemingly one news...
Exelixis ( NASDAQ: EXEL ) expects revenue for the fourth quarter to be $415M vs. consensus at $415.86M. For 2022, the company sees revenue of $1.6B vs. consensus at $1.6B. The company also said it expects 2023 revenue of $1.775B-$1.875B vs. consensus at $1.83B. Cabozantinib fr...
– Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. net product revenues for full year 2022, including approximately $375 million for fourth quarter 2022 – – Full year 2023 net product revenues guidance of $1,575 millio...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...